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A controlled trial of cyclophosphamide in patients with membranous
glomerulonephritis. Patients with membranous glomerulonephritis (MGN),
impaired renal function and the nephrotic syndrome are at high risk of
developing renal failure. Twenty—six such patients were studied with
serum creatinine concentrations exceeding 135 M, and 24-hour urine
protein excretion of at least 3.5 g/day to determine the potential benefit
of cyclophosphamide therapy. Cyclophosphamide (mean 1.5 mg/kg/day)
was given to nine patients for 23 4 months. These patients were
compared with 17 concurrent controls. The two groups did not differ in
clincial or laboratory features at the time of biopsy or start of treatment
or its equivalent. Six of the nine cyclophosphamide treated patients and
15 of the 17 controls had received prednisone therapy. The total
follow—up was 49 10 months in the treated group and 50 6 months
in the controls. At last observation, serum creatinine values exceeded
400 M in eight controls (4 on dialysis) and in none of the treated
patients. The mean serum creatinine level was significantly lower (P <
0.02) in the treated group (173 24 /.LM) than in controls (433 71/tM).
The mean serum albumin level and 24-hour urine protein excretion both
improved significantly with treatment as compared with controls. There
were four complete remissions, five partial remissions and no patient
with persistent nephrotic syndrome after treatment. In the controls,
there were no complete remissions, six partial remissions and II
patients had persistent nephrotic syndrome (P < 0.001). Thus, cyclo-
phosphamide therapy appears to be of benefit in patients with MGN,
the nephrotic syndrome and impaired renal function.
Membranous glomerulonephritis (MGN) is a condition char-
acterized by variable degrees of proteinuria, edema and renal
dysfunction, and up to 40% of affected adult patients progress
to end—stage renal disease [1—6]. Since the pathologic features
of MGN suggest that immune complex formation plays a role in
the pathogenesis of this condition [7, 8], various immunosup-
pressive agents either alone or in combination have been
utilized in an attempt to alter the natural history.
The literature remains unclear as to the appropriate therapeu-
tic approach to patients with MGN. At the present time, many
patients are treated with corticosteroid therapy on the basis of
previous studies [5, 9—15] however, recent evidence has ques-
tioned the long lasting benefit of corticosteroid therapy in
patients with MGN (D. Cattran, personal communication).
Similarly, there is lack of agreement as to the role of cyclophos-
phamide in this disease. There are some uncontrolled reports
documenting improvement with cyclophosphamide and corti-
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costeriod therapy [16—22]; however there is also a controlled
study in patients with stable renal function [23] and several
uncontrolled studies [3, 7, 24—28] which failed to demonstrate
benefit from cyclophosphamide therapy in patients with MGN.
Since patients with MGN, the nephrotic syndrome and a
degree of renal function impairment have a poor long—term
prognosis [21, 29], these subjects appeared to be the most
appropriate group in which to evaluate the possible benefit of
cyclophosphamide therapy. The treated patients were com-
pared with a concurrent (non-randomized) control group of
similar age range, biopsy date and peak serum—creatinine level.
The results indicate that the use of cyclophosphamide and
prednisone in patients with MGN, nephrotic range proteinuria
and impaired renal function is associated with a significant
improvement in both the degree of proteinuria and the level of
renal function.
Methods
The treatment group consisted of all the treated patients in
our institution who received cyclophosphamide and satisfied
the following criteria: (1.) MGN on renal biopsy; (2.) nephrotic
range proteinuria; and (3.) cyclophosphamide therapy for at
least 2 months.
The control group was chosen from the 227 patients with
biopsy proven MGN recorded in the Toronto Glomerulonephri-
tis Registry, who met the following criteria based on values
from the cyclophosphamide treated patients: (1.) renal biopsy in
the same time interval (December 1978 to November 1984); (2.)
the same age range at the time of renal biopsy (21 to 77 years);
(3.) nephrotic range proteinuria; (4.) two consecutive, peak
serum—creatinine concentrations in the same range as the
treated group (135 to 380 xM); and (5.) no prior treatment with
cyclophosphamide. MGN was diagnosed in all cases by the
standard criteria [30] on the basis of a biopsy studied by both
light and electron microscopy and immunofluorescent staining.
Staging was done according to Ehrenreich and Churg [31].
All biochemical and serological analyses were done using
standard laboratory methods. Nephrotic range proteinuria was
defined as being greater than or equal to 3.5 glday. A partial
remission was a sustained decrease in proteinuria to between
3.4 and 0.6 g/day and at least a 50% reduction in the 24-hour
urine protein excretion. A complete remission was a urine
protein excretion of 0.5 g/day or less.
To facilitate the comparison between the treated and control
groups, a "treatment equivalent point" was established for the
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Fig. 1. Course in cyclophosphamide treated patients with membranous
glomerulonephritis. The solid bar indicates nephrotic range proteinuria,
the hatched bar is partial remission and the open bar is complete
remission. Age at the time of biopsy is given in years. The time of
biopsy is indicated by an arrowhead with staging as defined in the
methods. Treatment duration is indicated by the length of the lines over
each bar with (sa.ma) being prednisone and (........ cyclophosphamide.
Serum creatinine concentration (MM) at the time of biopsy and at last
observation are indicated on the left and right of each bar, respectively
(normal values: <120 tM in males and <110 JSM in females). A death
) occurred with a serum urea concentration of 9.1 m (normal
range 3 to 7 mM).
control group as follows: Evaluation of the total follow—up
period post-biopsy in the cyclophosphamide treated patients at
the time of initial analysis (August 31, 1985) revealed that a
mean of 37% of their course occurred prior to the start of
therapy with 63% following this point. Therefore, the total
post-biopsy course in each control patient as of August 31, 1985
was divided similarly, with the treatment equivalent point
established as the closest data point to 37% of the interval
between the time of biopsy and the initial data analysis. The
total mean period of observation post-biopsy was 49 10
months in the cyclophosphamide treated group and 50 6
months in controls, with 16 6 and 14 2 months, respec-
tively, from biopsy to start of cyclophosphamide treatment (or
equivalent) and 33 5 and 36 4 months, respectively,
post-initiation of therapy.
Therapy
Corticosteriods. In the cyclophosphamide treated group, six
patients had previously received prednisone therapy (cases 1
through 5, 8). The maximum dosage was 60 mg daily or 125 mg
every other day (Fig. 1) for 7 2 (range 2 to 16) months. No
sustained response of either renal function or 24-hour urine
protein excretion was seen with this regimen. These six patients
also received concurrent cyclophosphamide and prednisone,
the latter in a mean initial dose of 33 9 mg/day. One patient
(case 5) had corticosteroid therapy discontinued after only one
month due to side effects. The prednisone dosage was changed
to alternate day therapy after the first month of treatment and
thereafter the dose was slowly tapered. The duration of therapy
for each patient is indicated in Figure 1. Three patients did not
receive coincident prednisone with the cyclophosphamide ther-
apy.
Case Sex Age stage
1 F 69 3 87'
_______________
2 M 44 2 159'
3 M 62 4 159IIW
4 M 47 2 265 _____________
5 M 29 3 159' 631*
6 M 47 3
7 M 46 1
8 M 63 3
9 F 73 4
10 M 25 2
11 M 35 4 ________
12 M 61 2 _______
13 M 73 3
14 M 61 2
15 M 41 3
16 M 63 1
17 M 54 2
Fig. 2. Course in control patients with membranous glomerulonephritis.
Legend is the same as Figure 1. End—stage renal disease requiring
dialysis and eventual transplantation is indicated ( * ). Two deaths
occurred ( f ) with the final serum creatinines as indicated.
Fifteen of the 17 control patients received prednisone therapy
(Fig. 2) for a mean of 20 4 (range 5 to 78) months. The
maximum dose was 50 to 125 mg alternate days in nine patients
and 40 to 80 mg daily in six. Steroid treatment did not appear to
influence the overall course of these patients.
Cyclophosphamide. Cyclophosphamide was given to the nine
treatment—group patients at a maximum dose of 2 mg/kg/day
(mean 100 mg/day, range 25 to 175 mg) and the dose was
adjusted to avoid leukopenia (<3,000 WBC/mm3). Treatment
was given for a mean of 23 4 (range 8 to 34) months. Seven
patients (Fig. 1) have had cytotoxic treatment discontinued
following a stabilization in their renal function and proteinurla.
One patient (case 2) relapsed and has had a second partial
remission following the reinstitution of therapy.
Other drugs. Three controls (cases 2, 4, 10) and three
cyclophosphamide treated patients (cases 1, 2, 6) were antico-
agulated with warfarin after thromboembolic events. Once
nephrotic range proteinuria and all symptoms of thromboem-
bolic phenomena were resolved, warfarin was discontinued in
the treated group (cases 1, 2). Long—term antihypertensive
therapy, including the use of beta—blockers and vasodilators,
was required in six cyclophosphamide treated and nine control
cases, while diuretics were given chronically to seven of the
former and 15 of the latter.
Statistical analysis
Student's t-test and the chi—square test were used where
applicable. The slopes of the reciprocal of the serum creatinine
concentrations were calculated for each patient pre- and post-
institution of treatment or treatment equivalent by linear regres-
sion analysis. The change in the reciprocal of the serum
creatinine level was tested using a repeated measure analysis of
Biopsy
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Biopsy
Case Sex Age stage
1 M 41 1
2 F 21 1
3 M 45 4
4 M 59 2
5 F 37 4
6 M 49 2
7 M 59 2
8 M 47 3
9 M 77 1
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Table 1. Clinical features at time of biopsy in patients with
membranous glomerulonephritis
Cyclophosphamide
treated % Controls %
N 9 17
Ageyears 48±5a 52±3
Sex, male/female 7/2 (78/22) 15/2 (87/13)
Hypertension 4 (44) 7 (41)
Edema 7 (78) 11(64)
Thromboembolic events 3 (33) 3b (18)
Pulmonary embolism I I
Renal vein thrombosis 2 3
Deep venous thrombosis — 1
Biopsy StageI&II 5(56) 8(47)
III & IV 4 (44) 9 (53)
a Mean SEM
b Case 2 had 3 thromboembolic events
variance (BMDP Statistical Software Inc. Los Angeles, Cali-
fornia, USA). A significant difference was defined as P less than
0.05. Results are reported as mean SEM wherever appropri-
ate.
Table 2. Laboratory features in patients with membranous
glomerulonephritis
Time of
biopsy
Initiation of
treatment
or
equivalent
Final
observation
Serum creatinine /LM
Treated 141 23 222 3I 173 24
Control 177 14 216 19 433 72b,c.e,
24-hour urine protein
excretion g/day
Treated 7.9 1.6 11.0 2.6 0.9 0.3""
Control 9.9 1.2 10.9 2.6 6.9 l.2'
Serum albumin g/liter
Treated 26 2 28 3 40
Control 23 2 28 2 33 2"
a p < 0.05 treatment initiation vs. time of biopsy
b P < 0.01 final observation vs. time of biopsy
c P < 0.01 final observation vs. treatment equivalent
d P < 0.01 final observation vs. treatment initiation
e P < 0.02 treated vs. control
P < 0.001 final observation vs. time of biopsy
g p < 0.02 final observation vs. treatment initiation
h p < 0.01 treated vs. control
'P < 0.05 treated vs. control
Results Renal function
Presentation
There was no significant difference in the clinical character-
istics at the time of biopsy of the nine treated patients and 17
controls (Table 1). The majority of patients were male; mean
age was 48 5 (range 21 to 77) years in the cyclophosphamide
group and 52 3 (range 25 to 73) years in the control group.
Most patients had edema and almost half required antihyper-
tensive treatment in each group. Thromboembolic events oc-
curred in 33% and 18% of cyclophosphamide treated and
control subjects, respectively, as detailed in Table 1. With the
exception of a control patient with sarcoidosis (case 15), no
patient had a systemic illness known to be associated with
MGN.
The pathologic stages are listed in Figures 1 and 2 and there
was no significant difference in the distribution between the two
groups (Table 1).
In all cyclophosphamide treated patients tested, serological
tests for cryoglobulin (6 of 6), C3 (9 of 9) and C4 (9 of 9) were
negative or within normal limits. Antinuclear antibody titers
were negative in seven while two had positive titers of 1/400 and
1/200; however, both of these patients (cases 2, 9) had a
negative LE cell preparation and the first one had a persistently
negative anti-DNA antibody test. Neither patient had sufficient
clinical or laboratory basis to support a diagnosis of systemic
lupus erythematosus. Patient 2 was also unusual in that she had
positive serum tests for both hepatitis B surface and e antigens.
However, there was no evidence of hepatic disease either
clinically or biochemically during eight years of observation.
Immunofluorescent staining failed to show hepatitis B surface
antigen in the renal biopsy. In the remaining treated patients the
test for hepatitis B surface antigen was negative. There were
incomplete serological data for the control patients.
In the cyclophosphamide group the mean serum creatinine
level was 141 23 M at the time of biopsy (Fig. 1, Table 2). In
the control group, the corresponding value was 177 14 sM
(Fig. 2, Table 2), At the start of cyclophosphamide therapy or
treatment equivalent, the mean serum creatinine values had
increased to 222 31 sM in the treated group and 216 19 ,SM
in the controls (Table 2). At the time of final observation, the
mean serum creatinine concentration has fallen slightly to 173
24 tM in the clophosphamide treated subjects and had in-
creased significantly to 433 72 M in the controls, a value
which was significantly higher than the treated group (P <
0.02). Case 8 (treated group) was omitted from the analysis of
serum creatinine levels at final observation as no value was
available. However, at the time of death this patient's serum
urea level was 9.1 m compared with a value of 11.0 m at the
start of treatment, suggesting at least a stabilization in renal
function.
The change in renal function was assessed by the slopes of
the reciprocal of the serum creatinine concentrations (l/Sc1)
before and after the treatment equivalent point. In the control
group, the mean slope was negative and did not differ signifi-
cantly between the two periods (Fig. 3), indicating continued
deterioration in renal function throughout the entire period of
observation. Although in the cyclophosphamide group the
mean slope of l/Sr pre-treatment was also negative and not
significantly different from that of the controls, in the treatment
period the mean slope became positive indicating improvement
in renal function. Repeated measure analysis of variance on the
same data showed a significant difference (P = 0.001) in the
mean slopes of l/Sr between the control and cyclophospha-
mide groups in the interval between the treatment initiation or
its equivalent and the final observation. In those patients in
whom a fall in serum creatinine concentration occurred, this
improvement was observed within four months of initiation of
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Fig. 3. Change in reciprocal of serum creatinine concentration in
patients with membranous glomerulonephritis treated with cyclophos-
phamide. The solid lines represent the least squares regression line
calculated from all the values of 1/Sr in the cyclophosphamide treated
group with patient numbers as shown (refer to Fig. 1). The length of the
line indicates duration of observation in years. The mean slopes for the
treated and control patient groups are indicated by the dashed and
dotted lines, respectively. These were significantly different in the
period following initiation of treatment or its equivalent by analysis of
variance (P = 0.001).
therapy, except for case 4 in whom this occurred only after 20
months of therapy.
Proteinuria
All patients had nephrotic range proteinuria at the time of
biopsy except for case 2 (cyclophosphamide treated) and case 9
(control). However, these two subjects both developed ne-
phrotic range proteinuria later in their course (Figs. 1, 2). The
mean 24-hour protein excretion at the time of biopsy was
similar in the two groups, 7.9 1.6 glday in the cyclophospha-
mide treated patients and 9.9 1.2 g/day in the controls (Table
2) and increased slightly by the start of treatment or equivalent
to 11.0 2.6 glday and 10.9 2.6 g/day, respectively. At this
time six treated and 10 control patients had a 24-hour urine
protein excretion in excess of 10 g. The mean 24-hour urine
protein excretion fell significantly following cyclophosphamide
treatment to 0.9 0.3 g/day (P < 0.01, which was significantly
lower than in the control group (P < 0.01, Table 2).
The classification of proteinuria at final follow—up is shown in
Table 3. In the cyclophosphamide treated group, four patients
had a complete remission versus none in the control group. A
partial remission was seen in five of the former and six of the
latter patients. Nephrotic range proteinuria persisted in 11 of
the controls and none of the treated patients. These differences
were significant, = 13.98 (P < 0.001).
Table 3. Outcome of proteinuria in patients with membranous
glomerulonephritis
Proteinuria
Cyclophosphamide
treated N (%)
Controls
N (%)
Nephrotic range 0 11(65)
Partial remission 5 (56) 6 (35)
Complete remission 4 (45) 0
= 13.98, P < 0.001
Serum albumin concentration
In the cyclophosphamide treated patients and controls, the
mean serum albumin level was low at the time of biopsy and
was unchanged at the start of treatment or equivalent (Table 2).
A rise in the mean values to 40 2 g/liter for the treated group
and 33 2 g/liter for the controls was seen at last observation.
This rise was only statistically significant in the former (P <
0.02) and the serum albumin was significantly higher in the
treated group as compared with the controls (P < 0.05).
Observations post-cyclophosphamide
In seven patients (cases 1 to 3, 5 to 7 and 9) cyclophospha-
mide therapy was discontinued after a mean of 21 3.2 months.
The mean serum creatinine in those seven cases was 198 /LM at
the time of cessation of therapy and 168 /LM at final observation.
24-hour urine protein was 1.6 grams and 1.3 grams at these two
periods, respectively, and serum albumin was 40 g/liter and 39
glliter. Thus the mean serum creatinine, 24-hour urine protein
excretion and serum albumin have remained stable for 14 2.2
months following cessation of cyclophosphamide therapy. There
was one relapse in the nephrotic syndrome Case 2 (Fig. 1) after
17 months of cessation of cyclophosphamide therapy, and this
patient has since responded to a second course of cyclophos-
phamide and prednisone therapy.
Complications of cyclophosphamide therapy
Case 8, a 47-year—old male with a previous myocardial
infarction, suffered a fatal second myocardial infarction after
eight months of cyclophosphamide therapy; his death was
unrelated to the treatment. Nine complications occurred which
could possibly be associated with cyclophosphamide therapy;
these included anemia (cases 3, 5, 7), gastric erosions (case 4),
amenorrhea (cases 2, 5), hair loss (case 5), and Varicella (cases
2 and 4) with one instance of pneumonitis (case 2). Only in the
last instance was temporary cessation of therapy required.
There was no occurrence of severe leukopenia (<2,000
WBC/mm3) or malignancy in the 175 patient months of obser-
vation after the start of the cytotoxic drug treatment.
Patient outcome
At final observation eight control patients had serum creati-
nine concentrations in excess of 400 M, four of whom required
therapy for end—stage renal disease (Fig. 2). Two patients have
died, both of whom had serum creatinine levels exceeding 500
/LM. In the cyclophosphamide treated group, the highest serum
creatinine level at last observation was 296 LM; none required
dialysis or transplantation. Although follow—up was limited in
case 8, he died with apparent stable renal function (final serum
urea 9.1 mM) while receiving cyclophosphamide,
48 36 24 12 12 24 36 48 60
Pre-treatment Post-treatment
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Discussion
Patients with membranous glomerulonephritis account for
approximately 2% of those presenting annually to end—stage
renal disease programs [32], with 20 to 60% of patients devel-
oping end—stage renal disease [1—6, 33—36]. The main indicators
of a poor prognosis are the nephrotic syndrome, an elevated
serum—creatinine concentration, adult age, male sex, and idio-
pathic disease [7, 12, 21, 29, 33].
The beneficial response of MGN to cyclophosphamide re-
ported by Suki and Chavez [16] prompted us to consider the use
of this agent for those patients at uniform high risk of develop-
ing renal failure, that is, those with both the nephrotic syn-
drome and moderately—reduced renal function. In this high risk
population there would be a greater likelihood of demonstrating
a beneficial response to any effective therapy. By restricting
cytotoxic therapy with potentially—severe adverse effects (leu-
kopenia, sterility, malignancy) to those patients at highest risk
of progression to end—stage renal disease the benefit to risk ratio
was maximized. In addition, the low cyclophosphamide dose (1
to 2 mg/kg/day) reduced the risk of drug related problems.
The use of the treatment equivalent point in the control group
allowed for retrospective comparisons between the controls
and the treated group. Although there is no precedent, this
approach appears to be valid based on the following points. The
laboratory parameters—serum creatinine and albumin concen-
trations and 24-hour urine protein excretion in the two groups..
were virtually identical at the start of treatment or equivalent
(Table 2) despite the arbitrary establishment of the treatment
equivalent point in the control group. In addition, the rates of
decline in l/Sr in the two patient groups did not differ signifi-
cantly over the interval between the time of biopsy and the
institution of treatment or its equivalent (Fig. 3).
With cyclophosphamide therapy, there was improvement in
renal function while deterioration continued in the controls.
With treatment the mean slope of i/Sc. became positive, and
the serum creatinine level in the treated patients was signifi-
cantly lower than in the controls (P < 0.02) at the time of final
observation. In association with this improvement in renal
function with cyclophosphamide therapy, there was a signifi-
cant decrease in the mean 24-hour urine protein excretion and a
rise in the mean serum—albumin concentration (Table 2). As
well, the number of patients with a complete or partial remis-
sion in proteinuria was significantly greater in the treatment
group compared with controls (Table 3).
The present study differs from the earlier studies using
cyclophosphamide therapy for MGN in several ways. Our
patients had a poor prognosis due to their impaired renal
function while all of those of Suki and Chavez [16] initially had
normal renal function and some of those reported by Donadio et
al [23] had neither nephrotic syndrome nor renal insufficiency.
The relatively good prognosis of these latter patients followed
for only one year likely contributed to the failure of that
controlled study to demonstrate a benefit of therapy with
cyclophosphamide. In the study by Tiller et al [24], which
combined warfarin and dipyridamole with cyclophosphamide,
neither the number of patients with the nephrotic syndrome nor
with renal insufficiency are detailed. Also, almost half of the
patients withdrew prior to the study completion. Failure of this
report to show benefit with cyclophosphamide may be due to a
possible detrimental effect of the antihemostatic drugs and an
unusually good prognosis in the control group.
The concurrent use of corticosteroids and cyclophosphamide
in our treated group makes the possible contribution of steroids
to the apparent treatment benefit difficult to assess. It is of
interest however that of the four patients with a complete
response, three received coincident corticosteroids. In addi-
tion, the one patient with a relapse did not gain a remission until
the prednisone dosage was increased to 20 mgm daily.
None of the patients in the study of Donadio et al [231
received concurrent prednisone and none improved. Thus it is
possible that there is an added benefit of corticosteroids to the
cyclophosphamide therapy in MGN. Further study of this
possible interaction is obviously required.
In an attempt to limit the adverse effects of cyclophospha-
mide, a relatively low dose was used initially (mean 1.5
mg/kg/day). This is lower than the mean dose (2 to 3 mg/kg/day)
used in the studies of Suki and Chavez [16] and Donadio et al
[23]. In these studies as well as in the present report, no serious
toxicity of cyclosphosphamide was observed.
Despite earlier disappointing results of therapy with the
chlorambucil in patients with MGN [36], Lagrue et a! [37] and
Ponticelli et a! [21, 38] have more recently reported benefit with
use of this agent. Patients with moderate renal insufficiency
(serum creatinine level greater than 133 or 150 M, respec-
tively) were excluded. Therefore, whether this treatment is
effective in those patients with more advanced renal insuffi-
ciency as in the present study is unclear. Ponticelli [21] empha-
sized the importance of the early institution of chlorambucil
therapy, in order to achieve a remission in patients with MGN.
However, in the current study of cyclophosphamide, two of the
patients who obtained a complete remission and two who had a
partial remission had the nephrotic syndrome for at least two
years prior to the institution of therapy (Fig. 1). As the
spontaneous remission rate of MGN is 20 to 25%, the early
institution of therapy would result in the unnecessary exposure
of these patients to a potentially toxic drug.
At present, we only offer cyclophosphamide therapy to those
individuals with either very symptomatic nephrotic syndrome
or reduced renal function. There is no necessity to treat patients
with MGN and the nephrotic syndrome in the absence of a
reduction in renal function unless the patient's symptoms
cannot be controlled with diuretics. We would not limit this
therapy to those with idiopathic membranous glomerulonephri-
tis as case 2, which might have been secondary to chronic
hepatitis B infection, had a dramatic response to this treatment
with no adverse effect. Cyclophosphamide should be used at a
low dose—I .5 mg/kg/day—as prolonged therapy may be re-
quired to achieve a remission, as has also been reported by
others [16]. Concurrent prednisone therapy has been associated
with the best results in our experience.
In summary, the effect of cyclophosphamide therapy in MGN
was studied in nine cyclophosphamide—treated patients com-
pared with 17 concurrent controls. All the subjects in this
controlled retrospective analysis were at high risk of developing
renal failure as they had renal insufficiency and the nephrotic
syndrome early in their course. Prolonged cyclophosphamide
treatment in low dose (1.5 mg/kg/day) was associated with a
lower mean serum creatinine concentration, reversal in the
mean slope of the reciprocal of the serum creatinine level, a fall
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in the mean 24-hour urine protein excretion, a 100% complete
and partial remission rate from the nephrotic syndrome and a
rise in the mean serum albumin concentration compared with
controls. This successful controlled experience with low—dose
cyclophosphamide treatment, albeit retrospective, should serve
as a stimulus for a prospective randomized trial of this agent in
high risk patients with MGN.
Note added in proof
A second patient (Case 1) had a relapse 28 months after
cessation of cyclophosphamide. He had gained a partial remis-
sion two months after the institution of cyclophosphamide
therapy.
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